OXFORD BIODYNAMICS LS-01
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor i… Read more
Market Cap & Net Worth: OXFORD BIODYNAMICS LS-01 (LMQ)
OXFORD BIODYNAMICS LS-01 (F:LMQ) has a market capitalization of $2.20 Million (€2.15 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #34939 globally and #4073 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OXFORD BIODYNAMICS LS-01's stock price €0.00 by its total outstanding shares 4290910967 (4.29 Billion).
OXFORD BIODYNAMICS LS-01 Market Cap History: 2020 to 2026
OXFORD BIODYNAMICS LS-01's market capitalization history from 2020 to 2026. Data shows change from $3.99 Billion to $2.20 Million (-71.55% CAGR).
OXFORD BIODYNAMICS LS-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OXFORD BIODYNAMICS LS-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LMQ by Market Capitalization
Companies near OXFORD BIODYNAMICS LS-01 in the global market cap rankings as of March 18, 2026.
Key companies related to OXFORD BIODYNAMICS LS-01 by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
OXFORD BIODYNAMICS LS-01 Historical Marketcap From 2020 to 2026
Between 2020 and today, OXFORD BIODYNAMICS LS-01's market cap moved from $3.99 Billion to $ 2.20 Million, with a yearly change of -71.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.20 Million | -83.33% |
| 2025 | €13.21 Million | -68.42% |
| 2024 | €41.84 Million | -96.17% |
| 2023 | €1.09 Billion | +103.28% |
| 2022 | €537.35 Million | -75.60% |
| 2021 | €2.20 Billion | -44.75% |
| 2020 | €3.99 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of OXFORD BIODYNAMICS LS-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.20 Million USD |
| MoneyControl | $2.20 Million USD |
| MarketWatch | $2.20 Million USD |
| marketcap.company | $2.20 Million USD |
| Reuters | $2.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.